Resultados globales: 10 registros encontrados en 0.08 segundos.
Artículos, Encontrados 9 registros
Documentos de investigación, Encontrados 1 registros
Artículos Encontrados 9 registros  
1.
10 p, 1.9 MB Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer / Codony Servat, Jordi (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Cuatrecasas Freixas, Miriam ; Asensio, Elena (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Montironi, Carla (Hospital Clínic) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Marín Aguilera, Mercedes (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Horndler, Carlos (Hospital Miguel Servet) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ; Jares, Pedro (Hospital Clínic) ; Reig, Oscar (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Victoria, Iván (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Gaba, Lydia (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ; Alonso, Vicente (Hospital Miguel Servet) ; Escudero, Pilar (Hospital Clínico Universitatio Lozano Blesa) ; Fernández-Martos, Carlos (Instituto Valenciano de Oncología) ; Feliu, Jaime (Hospital La Paz, CIBERONC) ; Méndez, Jose Carlos (Centro Oncológico de Galicia) ; Méndez, Miguel (Hospital de Móstoles) ; Gallego, Javier (Hospital de Elche) ; Salud, Antonieta (Hospital Arnau de Vilanova) ; Rojo, Federico (Pathology Department, Fundación Jiménez Diaz University) ; Castells, Antoni (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Prat, Aleix (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health) ; Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ; Maurel, Joan (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS))
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786  
2.
7 p, 242.6 KB Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies / Boeckx, N. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Koukakis, R. (Biostatistics, Amgen Ltd) ; Op de Beeck, K. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Rolfo, C. (Department of Oncology, Antwerp University Hospital, Edegem) ; Van Camp, G. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Douillard, J.-Y. (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ; André, T. (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ; Peeters, M. (Department of Oncology, Antwerp University Hospital, Edegem)
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of Oncology, Vol. 28 (april 2017) , p. 1862-1868  
3.
8 p, 357.7 KB Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer / Grasselli, J (Institut Català d'Oncologia) ; Élez Fernández, Mª Elena (Universitat Autònoma de Barcelona) ; Caratù, G (Vall d'Hebron Institut d'Oncologia) ; Matito, J (Vall d'Hebron Institut d'Oncologia) ; Santos, C (Institut Català d'Oncologia) ; Macarulla Mercadé, Teresa (Universitat Autònoma de Barcelona. Hospital Universitari de la Vall d'Hebron) ; Vidal, J (Hospital del Mar. Departament d'Oncologia) ; Garcia, M (Institut Català d'Oncologia) ; Viéitez, J M (Hospital Universitario de Asturias. Departamento de Oncologia Médica) ; Paéz, D (Institut d'Investigació Biomèdica Sant Pau) ; Falcó, E (Hospital Universitari Son Llatzer. Departament d'Oncologia Mèdica) ; Lopez Lopez, C (Hospital Universitario Marqués de Valdecilla. Departamento de Oncología Médica) ; Aranda, E (Hospital Universitario Reina Sofía (Córdoba). Departamento de Oncología Médica) ; Jones, F (Sysmex Inostics, Mundelein, USA) ; Sikri, V (Sysmex Inostics, Mundelein, USA) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Fasani, R (Vall d'Hebron Institut d'Oncologia) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona) ; Montagut, C (Hospital del Mar. Departament d'Oncologia) ; Azuara, D (Institut Català d'Oncologia) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Salazar, R (Institut Català d'Oncologia) ; Vivancos, A (Vall d'Hebron Institut d'Oncologia)
Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in tumor tissue and ctDNA in metastatic colorectal cancer (mCRC) patients to establish eligibility for anti-epidermal growth factor receptor (EGFR) therapy. [...]
2017 - 10.1093/annonc/mdx112
Annals of Oncology, Vol. 28 (march 2017) , p. 1294-1301  
4.
7 p, 770.6 KB Proxies of quality of life in metastatic colorectal cancer : analyses in the RECOURSE trial / Van Cutsem, Eric (University Hospitals Leuven and KU Leuven) ; Falcone, Alfredo (Azienda Ospedaliero-Universitaria Pisana) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre/i+12) ; Komatsu, Yoshito (Hokkaido University Hospital) ; Pastorino, Alessandro (IRCCS AOU San Martino IST) ; Peeters, Marc (Antwerp University Hospital) ; Shimada, Yasuhiro (National Cancer Center Hospital) ; Yamazaki, Kentaro (Shizuoka Cancer Center) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Zaniboni, Alberto (Fondazione Poliambulanza) ; Amellal, Nadia (Institut de Recherches Servier) ; Kanehisa, Akira (Institut de Recherches Servier) ; Winkler, Robert (Taiho Oncology) ; Makris, Lukas (Taiho Oncology) ; Mayer, Robert J (Dana-Farber Cancer Institute) ; Ohtsu, Atsushi (National Cancer Center Hospital East) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona. Deaprtament de Medicina)
In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). [...]
2017 - 10.1136/esmoopen-2017-000261
ESMO Open, Vol. 2 (november 2017)  
5.
9 p, 1023.2 KB Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial / Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal) ; Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ; Tabernero Caturla, Josep (Hospital Universitari Vall d'Hebron) ; Cervantes, A. (Universitat de València) ; Grávalos, Cristina (Hospital Universitario Doce de Octubre) ; Pericay, Carles (Corporació Sanitària Parc Taulí) ; Gil Calle, S. (Hospital Carlos Haya) ; Mizuguchi, Hirokazu (Taiho Oncology) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío) ; García Carbonero, Rocio (Hospital Universitario Doce de Octubre) ; Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235  
6.
9 p, 306.4 KB Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer / Élez Fernández, Mª Elena (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Hendlisz, A. (Institut Jules Bordet (Belgium)) ; Delaunoit, T. (Centres Hospitaliers Jolimont (Belgium)) ; Sastre, J. (Hospital Universitario San Carlos) ; Cervantes, A. (Universitat de València. INCLIVA Institut d'Investigació Sanitària) ; Varea, R. (Eli Lilly and Company (Spain)) ; Chao, G. (Eli Lilly and Company (USA)) ; Wallin, J. (Eli Lilly and Company (Suècia)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Universitat Autònoma de Barcelona
This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). [...]
2016 - 10.1038/bjc.2015.480
British Journal of Cancer, Vol. 114 (February 2016) , p. 372-380  
7.
8 p, 207.5 KB Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer / Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Cervantes, A (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Roselló, S (Universidad de Valencia. Biomedical Research Institute (INCLIVA)) ; Van Cutsem, E (University Hospitals Gasthuisberg and KU Leuven) ; Tejpar, S (University Hospitals Gasthuisberg and KU Leuven) ; Prenen, H (University Hospitals Gasthuisberg and KU Leuven) ; Martinelli, E (Second University of Naples. Department of Experimental and Clinical Medicine) ; Troiani, T (Second University of Naples. Department of Experimental and Clinical Medicine) ; Laffranchi, B (Merck Serono SA) ; Jego, V (Merck Serono SA) ; von Richter, O (Merck KGaA) ; Ciardiello, F (Second University of Naples. Department of Experimental and Clinical Medicine) ; Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881  
8.
15 p, 3.0 MB Epigenetic inactivation of the extracellular matrix metallopeptidase ADAMTS19 gene and the metastatic spread in colorectal cancer / Alonso, Sergio (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; González, Beatriz (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Ruiz-Larroya, Tatiana (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Durán Domínguez, Mercedes (Instituto de Biología y Genética Molecular (Valladolid)) ; Kato, Takaharu (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Matsunaga, Akihiro (Sanford Burnham Prebys Medical Discovery Institute (Califòrnia)) ; Suzuki, Koichi (Jichi Medical University (Japó)) ; Strongin, Alex Y. (Sanford Burnham Prebys Medical Discovery Institute (Califòrnia)) ; Giménez Bonafé, Pepita (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Perucho, Manuel (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer)
BACKGROUND: ADAMTS19 encodes a member of the ADAMTS (a disintegrin and metalloproteinase domain with thrombospondin motifs) protein family with emerging roles in carcinogenesis and metastasis. ADAMTS shares several distinct protein modules including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. [...]
2015 - 10.1186/s13148-015-0158-1
Clinical Epigenetics, Vol. 7, No. 124 (December 2015)  
9.
27 p, 8.4 MB Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model / Álamo, Patricia (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Gallardo Alcañiz, Alberto (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Di Nicolantonio, Federica (Università degli studi di Torino. Dipartimento di Oncologia) ; Pavón Ribas, Miguel Ángel (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Casanova, Isolda (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Trias Folch, Manuel (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Mangues i Bafalluy, Ma. Antònia (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya). Servei de Cirurgia General i Digestiva) ; Lopez-Pousa, Antonio (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Bardelli, Alberto (Università degli studi di Torino. Dipartimento di Oncologia) ; Céspedes, María Virtudes (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina) ; Mangues, Ramón (Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina)
Although all KRas (protein that in humans is encoded by the KRas gene) point mutants are considered to have a similar prognostic capacity, their transformation and tumorigenic capacities vary widely. [...]
2015 - 10.1096/fj.14-262303
The FASEB journal, Vol. 29 Issue 2 (Feb. 2015) , p. 464-476  

Documentos de investigación Encontrados 1 registros  
1.
43 p, 654.6 KB Impacte de les mutacions del gen kras en pacients afectes de càncer colorectal metastàtic i la seva relació amb els tractaments biològics associats a la quimioteràpia / Pàmpols i Felip, Montse ; Pericay Pijaume, Carles, dir. (Parc Taulí de Sabadell) ; Calvet Calvo, Xavier, dir. (Universitat Autònoma de Barcelona. Departament de Medicina) ; Universitat Autònoma de Barcelona. Departament de Medicina
El càncer colorectal és un dels càncers més comuns i amb major prevalença, presentant una supervivència als 5 anys per sota del 20% sense tractament.
2013  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.